Anti-thymocyte globulin

Autologous Stem Cell Transplantation for Crohn's Disease

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Islet Transplantation in Patients With "Brittle" Type I Diabetes

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Personalized NK Cell Therapy in CBT

Uterine Transplant in Absolute Uterine Infertility (AUIF)

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Autologous Stem Cell Transplant for Crohn's Disease

Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Stem Cell Transplantation in Crohn's Disease

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Haploidentical HCT for Severe Aplastic Anemia

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Methods of T Cell Depletion Trial (MoTD)

Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft

Combined Kidney and Hematopoietic Stem Cell Transplantation for Tolerance Induction

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression

Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide

Advancing Transplantation Outcomes in Children

Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome

PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

A Study of Emapalumab for Pediatric Aplastic Anemia

Precision Administration of Anti-thymocyte Globulin With or Without Verapamil

Modified Second Haplo-transplantation for Graft Failure

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

ATG Individualized Dosing Model in URD-PBSCT.

Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years

Haplo-HSCT for Myelofibrosis

Immunological Reset to Allow Access to HLA Compatible Transplantation in Highly Sensitized Kidney Transplant Candidates Through Non-myeloablative Autologous Stemm Cell Transplantation

Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia

Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia

Allo HSCT for High Risk Hemoglobinopathies

Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy

A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors

Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study

Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Immune Tolerance Induction After Liver Transplantation

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors

A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA

Haplo-Cord HSCT for AML/MDS

Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)

Individualized Application of Anti-Thymocyte Globulin(ATG)in Unrelated Donor Hematopoietic Stem Cell Transplantation

Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT

Anti-CD25 Monoclonal Antibody for Prevention of Acute GVHD After Haploidentical HSCT

Population PK-guided ATG Dosing in Haplo-HSCT

Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders

Comparing Therapies for the Treatment of Severe Aplastic Anemia

Medical Treatment for Diamond Blackfan Anemia

A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome

Combination Therapy of Severe Aplastic Anemia

Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease

Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia

Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Biological Therapy in Treating Patients With Myelodysplastic Syndrome

Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders

Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Bone Marrow Transplantation in Treating Patients With Leukemia

Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome

Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis

Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus

Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia

Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma

Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases

Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia

Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients

Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Scleroderma: Cyclophosphamide or Transplantation

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation

Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus

Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids

T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders

Stem Cell Transplantation for Hematological Malignancies

Stem Cell Transplant for Hemoglobinopathy

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Stem Cell Transplant for Bone Marrow Failure Syndromes

Stem Cell Transplant for Inborn Errors of Metabolism

Stem Cell Transplantation for Hurler

Stem Cell Transplant for Hematological Malignancy

The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Allogeneic Transplantation From Related Haploidentical Donors

TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease

Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans

A Study of Mycophenolate Mofetil and Cyclosporin, Without Concomitant Corticosteroids, After a First Renal Transplant

Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia

Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients

Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies

A Study That Will Look at the Impact of Immunosuppression on Antibody Production in Kidney Transplant Recipients.

Hematopoietic Stem Cell Support in Vasculitis

Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma

Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes

Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation

Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus

Simultaneous Pancreas-kidney Transplantation With Campath Protocol

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs

Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant

Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma

Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients

Thymoglobulin (ATG) Dose Finding Study

Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Islet Transplantation in Type 1 Diabetes

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Strategies to Improve Islet Survival

Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome

Efficacy of Islet After Kidney Transplantation

B-Lymphocyte Immunotherapy in Islet Transplantation

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

Cord Blood Expansion on Mesenchymal Stem Cells

Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

Myfortic vs. Cellcept in Kidney Transplant Recipients

Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation

Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Improved Induction and Maintenance Immunosuppression in Kidney Transplantation

A Study of Thymoglobulin and Tacrolimus in Liver Transplant

Parathyroid and Thymus Transplantation in DiGeorge #931

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus

Phase I/II Thymus Transplantation With Immunosuppression #950

Thymus Transplantation With Immunosuppression

Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation

Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant

Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Induction Related BK Viremia in Renal Transplant Patients

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases

A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma

Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation

Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol

Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation

Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome

Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome

Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor

Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases

Allogeneic Hematopoietic Stem Cell Transplantation

Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST)

Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients

Randomized Trial for Mixed Acute Rejection

Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT

Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

Hematopoietic Stem Cell Transplant in Devic's Disease

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Autologous and Allogeneic Transplant for Relapsed Lymphoma

Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment

Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies

Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab

Serum-Free Thymus Transplantation in DiGeorge Anomaly

A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease

Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists

Comparison of ATG to Thymoglobuline in Renal Transplantation

Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)

Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)

Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML

Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients

Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation

Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies

Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin

Pilot Study of Unrelated Cord Blood Transplantation

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation

Combined Haploidentical-Cord Blood Transplantation for Adults and Children

Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment

Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia

Sickle Cell Disease Conditioning for Bone Marrow Transplant

Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant

Infusion of Expanded Cord Blood T Cells

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

Unrelated Double Umbilical Cord Blood Units Transplantation

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission

Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation

Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Autologous Stem Cell Transplant for Multiple Sclerosis

Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis

Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia

Reversing Type 1 Diabetes After it is Established

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants

Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia

Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)

Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.

rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation

Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation

Reparixin in Pancreatic Islet Transplantation

Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia

Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis

Thymoglobulin Induction in Kidney Transplant Recipients

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS)

A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance

Nonmyeloablative Allogeneic Transplant

Studies of Kidney Transplant Outcome

A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

Low Dose Thymoglobin in Renal Transplant Patients

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia

De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction

Research Study of ATG and Rituximab in Renal Transplantation

Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients

Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica

Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes

Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation

Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate

Cord Blood Transplantation for Patients With Cancer

Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells

NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Scleroderma Treatment With Autologous Transplant (STAT) Study

Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

PRO#0118: Decitabine Plus Mini Flu-Bu

Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors

Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation

Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Multi-Drug Desensitization Protocol for Heart Transplant Candidates

Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease

Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies

Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies

Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

Allogeneic Stem Cell Transplant for CLL

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors

Busulfan and Cyclophosphamide Followed By ALLO BMT

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Belatacept Early Steroid Withdrawal Trial

Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas

Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

T&B Depletion Non Malignant

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA

Non-Myeloablative Conditioning and Bone Marrow Transplantation

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis

Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis

ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria

Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis

Thymoglobulin in Cadaver Donor

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes

Comparing Everolimus and Sirolimus in Renal Transplant Recipients

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

Evaluation of 3 Different Doses of IV Busulfan

Preemptive Therapy of GVHD

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents

Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF

Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)

Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

hATG+CsA vs hATG+CsA+Eltrombopag for SAA

Single Dose rATG for Renal Allograft Rejection

Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

Regimen Optimization Study

Effects of Thymoglobulin on Human B Cells

Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients

Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease

Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Haploidentical Hematopoietic Stem Cell Transplantation

Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia

ATG-GCSF in New Onset Type 1 Diabetes

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

Pilot Study of Stem Cell Transplantation for Children and Young Adults With Refractory Crohn's Disease.

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

B Cell Induction in Pediatric Lung Transplantation

Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients

Expanded Access Protocol Thymus Transplantation

Stem Cell Transplantation for Stiff Person Syndrome (SPS)

ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors

Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies

A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia

Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg)

HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome

Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases

Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation

A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation

Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance

European Transplant Registry of Senior Renal Transplant Recipients on Advagraf

Effect of BM-MSCs in DCD Kidney Transplantation

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

Diabetes Islet Preservation Immune Treatment

Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT